LEXX Lexaria Bioscience Corp. Stock Quote

LEXX [NASD]

Consumer Defensive | Packaged Foods | Canada

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	4.70%	Shs Outstand	4.05M	Perf Week	-5.70%
Market Cap	25.06M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.86M	Perf Month	-26.38%
Income	-3.70M	PEG	-	EPS next Q	-	Inst Own	0.10%	Short Float	10.32%	Perf Quarter	4.80%
Sales	0.60M	P/S	41.76	EPS this Y	10.30%	Inst Trans	-	Short Ratio	1.41	Perf Half Y	-13.51%
Book/sh	2.90	P/B	1.66	EPS next Y	-	ROA	-46.20%	Target Price	-	Perf Year	-48.39%
Cash/sh	1.88	P/C	2.56	EPS next 5Y	-	ROE	-48.90%	52W Range	3.98 - 15.64	Perf YTD	-35.82%
Dividend	-	P/FCF	-	EPS past 5Y	-0.60%	ROI	-163.40%	52W High	-69.30%	Beta	1.68
Dividend %	-	Quick Ratio	27.10	Sales past 5Y	92.10%	Gross Margin	74.80%	52W Low	20.75%	ATR	0.40
Employees	4	Current Ratio	27.40	Sales Q/Q	78.90%	Oper. Margin	-	RSI (14)	34.36	Volatility	4.89% 7.87%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	127.80%	Profit Margin	-	Rel Volume	0.15	Prev Close	4.96
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	208.98K	Price	4.80
Recom	1.00	SMA20	-11.30%	SMA50	-21.77%	SMA200	-34.92%	Volume	33,096	Change	-3.23%

Apr-15-21 04:05PM	Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants ACCESSWIRE
08:58AM	Lexaria Bioscience: Turning the Tide on Hypertension Newsfile
Apr-14-21 07:00AM	Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network ACCESSWIRE
Apr-08-21 08:30AM	Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion Marketplace Newsfile
Apr-06-21 07:05AM	Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets ACCESSWIRE
Mar-24-21 07:00AM	Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages ACCESSWIRE
Mar-23-21 07:00AM	Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET ACCESSWIRE
Mar-16-21 07:00AM	Lexaria's Antiviral Drug Evaluation Program Progressing ACCESSWIRE +5.85%
Mar-15-21 07:00AM	Rapid Progress in Hypertension Studies by Lexaria ACCESSWIRE
Mar-11-21 07:10AM	Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021 ACCESSWIRE
Mar-09-21 08:30AM	Could DehydraTECH(TM) CBD be Worth $3 Billion a Year to Lexaria? Newsfile
Feb-16-21 06:00AM	Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection CNW Group
Feb-11-21 07:15AM	Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies ACCESSWIRE
Feb-09-21 08:30AM	Lexaria Outlook is Promising After Jazz Acquisition of GW Newsfile +12.63%
Feb-01-21 06:30AM	Lexaria Provides Guidance on Upcoming R&D ACCESSWIRE
Jan-28-21 10:09AM	Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast Newsfile
Jan-15-21 03:35PM	Lexaria Appoints New Board Member ACCESSWIRE
06:30AM	Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants ACCESSWIRE

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience